Back to search
FDAFDA · Food and drugs·Recall number D-0380-2026

Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-106-03; d) 50g, NDC 84385-106-04; e) 100g, NDC 84385-106-05Manufacturer: Harbin Jixianglong Biotech Co., Ltd., North of Baoan Road, East of Changqing Street, Limin Development Zone, Harbin, China.

Published March 11, 2026 · Recall initiated: February 13, 2026

Summary

FDA records drug Class II recall D-0380-2026, published March 11, 2026 and initiated February 13, 2026. Recalling firm: Harbin Jixianglong Biotech Co., Ltd.; Status: Ongoing; Reported quantity: N/A; Lot: Batch # CP-030-20250911, Mfg Date: Sep. 25th, 2025, Retest Date: Sep. 24th, 2027. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution

What to do

Voluntary: Firm initiated · E-Mail

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Harbin Jixianglong Biotech Co., Ltd.
Distributor
Nationwide within the United States
Lot
Batch # CP-030-20250911, Mfg Date: Sep. 25th, 2025, Retest Date: Sep. 24th, 2027.
Risk classification
Class II
Area (FDA)
drug
Country
China

Related recalls

Questions about this recall

Was Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-106-03; d) 50g, NDC 84385-106-04; e) 100g, NDC 84385-106-05Manufacturer: Harbin Jixianglong Biotech Co., Ltd., North of Baoan Road, East of Changqing Street, Limin Development Zone, Harbin, China. recalled?

Yes. FDA published recall D-0380-2026 on March 11, 2026. Reported hazard: CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution

What should I do if I have this product?

Voluntary: Firm initiated · E-Mail